The FDA has required stronger warnings that medicines containing carbidopa and levodopa can deplete vitamin B6 and, in rare severe cases, contribute to seizures. The combination remains a cornerstone of Parkinson’s treatment because it restores dopamine signaling and improves movement symptoms. The warning calls for laboratory monitoring and clinically directed supplementation.
The agency acted on March 20, 2026, and covered multiple pills, intestinal suspension and infusion products. The warning follows exposure to carbidopa and levodopa across formulations rather than one particular pill.
Carbidopa helps levodopa reach the brain
Parkinson’s disease reduces dopamine-producing neurons, causing tremor, stiffness and slowed movement. Levodopa is converted into dopamine, while carbidopa limits conversion elsewhere in the body so more levodopa can reach the brain and fewer peripheral side effects occur.
Products include Sinemet, Rytary, Crexont, Dhivy, Duopa and other formulations. Some add entacapone, while an infused prodrug is converted into active carbidopa and levodopa in the body.
The same chemistry can reduce active vitamin B6
Vitamin B6 supports amino-acid metabolism and neurotransmitter production. Levodopa metabolism consumes B6-related capacity, and carbidopa can bind the vitamin’s active form, creating an additional functional loss.
The FDA communication says higher carbidopa/levodopa doses may increase deficiency risk. The agency recommended checking baseline B6 levels, monitoring periodically during treatment and testing when symptoms appear.
Fourteen reviewed seizure cases drove the warning
The FDA identified 14 cases tied to B6 deficiency, including 13 postmarketing reports and one from medical literature. Every reviewed case involved more than 1,000 milligrams of levodopa per day, and doses above 1,500 milligrams were associated with a shorter time to recognized deficiency.
Latency ranged from 23 to 132 months, showing that the problem can emerge after long treatment. Two deaths occurred. Among nine patients treated with vitamin B6, all nine had seizure resolution even though most had not responded to several standard anti-seizure medicines.
Symptoms can appear before a seizure
B6 deficiency can contribute to depression, confusion, inflammation around the lips and tongue, skin changes and nerve damage causing numbness, tingling, sharp pain or weakness. Anemia and elevated homocysteine appeared in some reviewed cases.
Those signs overlap with other illnesses and treatment effects. Laboratory evaluation and medication review are needed to distinguish deficiency from disease progression, another nutritional problem or an unrelated neurological condition.
Supplementation requires clinical supervision
The FDA advised supplementation as necessary in consultation with a health professional. Taking large doses independently is not risk-free because excessive long-term B6 can itself cause nerve injury.
A clinician can select a dose based on blood levels, symptoms, diet and the Parkinson’s regimen. Monitoring after supplementation can confirm whether levels and neurological signs improve while preserving the benefit of levodopa.
The warning does not mean treatment has become unsafe for everyone
The reviewed cases were rare and concentrated among high-dose exposures. Spontaneous reports cannot calculate an exact incidence, and underreporting is possible. The FDA nevertheless found reasonable evidence of a causal association strong enough for label changes.
Stopping levodopa abruptly can cause severe worsening and, in some circumstances, a dangerous syndrome resembling neuroleptic malignant syndrome. Treatment changes require a prescribing clinician unless emergency personnel direct otherwise.
The durable lesson is practical: long-term carbidopa/levodopa therapy can affect a vitamin essential to the nervous system, so monitoring belongs beside symptom control. The FDA’s March action covered the full drug class.
Dose and duration help identify higher-risk situations
Advanced Parkinson’s disease can require larger or more frequent levodopa doses as symptom control becomes less predictable. Continuous intestinal or subcutaneous delivery may reduce motor fluctuations, but total daily exposure still matters when assessing vitamin metabolism.
The reviewed seizure cases clustered at high doses and after years of treatment. That pattern supports periodic monitoring rather than assuming a normal level at treatment start remains normal indefinitely. It also gives clinicians a reason to investigate unexplained neurological changes before adding multiple anti-seizure medicines.
A deficiency seizure may require a different response
Several reported seizures failed to improve with conventional anti-seizure therapy but resolved after vitamin B6. That does not make B6 a universal seizure treatment. It highlights the importance of identifying a specific metabolic cause when the usual approach is ineffective.
Status epilepticus, a prolonged or repeated seizure without recovery, occurred in some cases and is a medical emergency. Rapid assessment can include glucose, electrolytes, medication exposure and nutritional markers alongside neurological evaluation.
Other B6-related findings can strengthen the diagnosis. Elevated homocysteine, anemia, neuropathy and neuropsychiatric changes appeared in portions of the FDA case series. No single feature is exclusive to deficiency, but a cluster aligned with high-dose carbidopa/levodopa raises suspicion.
Product diversity matters because tablets are only one form of carbidopa/levodopa therapy. The FDA’s rationale applied across the entire drug class. Monitoring advice follows exposure to the active drugs, not merely the shape or route of a dose.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
